- Home
- Signaling Pathways
- Others
- Others
- 4-Methylumbelliferone (4-MU)
4-Methylumbelliferone (4-MU)
IC50: 0.4 mM
4-Methylumbelliferone is a hyaluronic acid (HA) synthesis inhibitor. The activation of HAS2 and the over-production of HA are existed in many metastatic tumor cell lines. Increased synthesis of HA is often associated with increased metastatic potential and invasivity in tumor cells.
In vitro: 4-Methylumbelliferone (MU), an inhibitor of HA synthesis, has been studied as a potential anti-tumor drug on account of inhibiting the growth of primary tumors and distant metastasis of tumor cells. The mechanism still needs to be clarified, although several studies revealed that the anticancer effects of MU are mediated by inhibition of HA signal pathway. In a previous study the regulation of HA synthesis was demonstrated by ceramide, and now show how MU activated NSMase2 generates ceramides and mediates MU modulated inhibition of HA synthesis (cell migration and invasion, and apoptosis of tumor cells). Using a HA enriched mouse oligodendroglioma cell line G26-24, it was found that MU elevated the activity of NSMase2 and enhanced ceramide levels, which in turn potentiated phosphatase PP2A activity. Further, the activated PP2A decreased phosphorylation of Akt, reduced activities of HA synthase2 (HAS2) and calpains, and blocked both the synthesis of HA, and the migration and invasion of G26-24 tumor cells. In addition, MU mediated ceramide induced activation of p53 and caspase-3, decreased SIRT1 expression and deduced G26-24 viability. The mechanism of the MU anticancer therefore initially involves NSMase2/ceramide/PP2A/AKT/HAS2/caspase-3/p53/SIRT1 and the calpain signaling pathway, indicating that ceramides play a important role in the ability of a tumor to become aggressively metastatic and grow [1].
In vivo: So far, no study in vivo has been conducted.
Clinical trial: Clinical study has been conducted.
Reference:
[1] Qin J, Kilkus J, Dawson G. The hyaluronic acid inhibitor 4-methylumbelliferone is an NSMase2 activator-role of Ceramide in MU anti-tumor activity. Biochim Biophys Acta. 2016 Feb;1861(2):78-90.
Physical Appearance | A solid |
Storage | Desiccate at -20°C |
M.Wt | 176.17 |
Cas No. | 90-33-5 |
Formula | C10H8O3 |
Solubility | insoluble in H2O; ≥2.45 mg/mL in EtOH with gentle warming and ultrasonic; ≥8.8 mg/mL in DMSO |
Chemical Name | 7-hydroxy-4-methyl-2H-chromen-2-one |
SDF | Download SDF |
Canonical SMILES | CC(C1=C(O2)C=C(O)C=C1)=CC2=O |
Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Cell experiment:[1] | |
Cell lines |
HMEC and RF-24 endothelial cells |
Reaction Conditions |
0 ~ 2 mM 4-MU for 3 d incubation |
Applications |
4-MU inhibited the proliferation of actively growing HMEC and RF-24 endothelial cells in a dose-response manner. The half-maximal inhibitory concentration (IC50) values in the proliferation assay were 0.65 ± 0.04 and 0.37 ± 0.03 mM for HMEC and RF-24 cells, respectively. |
Animal experiment:[1] | |
Animal models |
Embryos from a transgenic (TG(fli1:EGFP)y1) zebrafish line |
Dosage form |
0.2 mM 24 h treatment |
Applications |
A 24 h treatment with 0.2 mM 4-MU inhibited the proper growth of intersegmental vessels, which indicated the antiangiogenic effect of this compound. Thus, 4-MU could be potentially used for antiangiogenic therapy. |
Note |
The technical data provided above is for reference only. |
References: 1. García-Vilas JA, Quesada AR, Medina Má. 4-methylumbelliferone inhibits angiogenesis in vitro and in vivo. Journal of Agricultural and Food Chemistry, 2013, 61(17): 4063-4071. |
Description | 4-Methylumbelliferone(4-MU) is an inhibitor of hyaluronic acid (HA) synthesis with an IC50 value of 0.4 mM. | |||||
Targets | ||||||
IC50 |
Quality Control & MSDS
- View current batch:
Chemical structure
